DVI-001

Inflammatory Bowel Disease

PreclinicalApproaching PCC selection

Key Facts

Indication

Inflammatory Bowel Disease

Phase

Preclinical

Status

Approaching PCC selection

Company

AI-driven drug discovery company using molecular dynamics and AI to design novel therapeutics for autoimmune and metabolic diseases.

Drug	Company	Phase	Status
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
IBD Subclassification	Bio-Me	Research	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
TRWR‑IBD	Taiwan Resonant Waves Research	Preclinical	Active